Table 2

Risk of subjects developing new airways obstruction following treatment with unselective and selective topical β antagonist compared to controls

Number of new TBA casesNumber of unexposed subjects (group C)Unadjusted rate ratio (95% CI)Adjusted hazard ratio (95% CI)
TBA-U  =  unselective topical β antagonist treated subjects; TBA-S  =  selective topical β antagonist treated subjects.
*p<0.01; **p<0.001.
TBA-U treated subjects69/2321 (3.0%)112/9094 (1.2%)2.30** (1.69 to 3.12)2.22** (1.63 to 3.02)
TBA-S treated subjects12/324 (3.7%)3.06** (1.67 to 5.54)2.96** (1.63 to 5.36)